<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931957</url>
  </required_header>
  <id_info>
    <org_study_id>860241-5807</org_study_id>
    <nct_id>NCT00931957</nct_id>
  </id_info>
  <brief_title>Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease</brief_title>
  <official_title>Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find if Etanercept can improve the outcome of ocular lesions
      of Behcet's Disease treated with Methotrexate and Prednisolone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test in a randomized single blind control trial the efficacy of Etanercept in patients
      with posterior uveitis and/or retinal vasculitis of Behcet's disease treated with
      Methotrexate and prednisolone
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity, Disease Activity Index (DAI) for Posterior Uveitis, DAI for Retinal vasculitis</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAI for Anterior Uveitis, Total Inflammatory Acitivity Index, Total Adjusted Disease Activity Index</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Behcet Syndrome</condition>
  <condition>Uveal Disease</condition>
  <arm_group>
    <arm_group_label>Etanercept-MTX-Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate + Prednisolone + Etanercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, MTX-Prednisolone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate + Prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept, Methotrexate, Prednisolone</intervention_name>
    <description>In: Arm A, Etanercept-MTX-Prednisolone:
Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.
In Arm B:
Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.</description>
    <arm_group_label>Etanercept-MTX-Prednisolone</arm_group_label>
    <arm_group_label>B, MTX-Prednisolone</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Behcet's Disease according to the International Criteria for Behcet's disease (ICBD)

          -  Active posterior uveitis and/or retinal vasculitis

        Exclusion Criteria:

          -  Visual acuity inferior to 1/10 on Snellen chart

          -  Being under cytotoxic drugs or having received them in the past 2 months

          -  Not being able to follow the one year treatment and the regular follow ups
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fereydoun Davatchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rheumatology Research Center, Medical Sciences/University of Teheran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fereydoun Davatchi, MD</last_name>
    <phone>(98-21) 8802-6956</phone>
    <email>fddh@davatchi.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bahar Sadeghi, MD</last_name>
    <phone>(98-21) 8820-6956</phone>
    <email>bahar@bahars.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Research Center, Behcet's Disease Unit (Shariati Hospital)</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fereydoun Davatchi, MD</last_name>
      <phone>(98-21)8802-6956</phone>
      <email>fddh@davatchi.net</email>
    </contact>
    <contact_backup>
      <last_name>Bahar Sadeghi, MD</last_name>
      <phone>(98-21)8802-6956</phone>
      <email>bahar@bahars.net</email>
    </contact_backup>
    <investigator>
      <last_name>Fereydoun Davatchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farhad Shahram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hormoz Shams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdolhadi Nadji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bahar Sadeghi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massoomeh Akhlaghi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tahereh Faezi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://rrc.tums.ac.ir/</url>
    <description>Rheumatology Research Center, Medical Sciences/University of Tehran</description>
  </link>
  <reference>
    <citation>Melikoglu M, Ozvazgan y Fresko I et al. The response of treatment resistant uveitis in Behcet's syndrome (BS) to a TNF-α blocker, Etanercept: an open study. Arthritis Rheum 2002; 46: S181, (Abstract) 400</citation>
  </reference>
  <reference>
    <citation>Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, Akbarian M, Gharibdoost F. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. Adv Exp Med Biol. 2003;528:579-84.</citation>
    <PMID>12918769</PMID>
  </reference>
  <reference>
    <citation>Davatchi F. New and innovative therapies for Behcet's Disease. APLAR Journal of Rheumatology 2004; 7: 141-145</citation>
  </reference>
  <reference>
    <citation>Davatchi F, Shams H, Nadji A, Jamshidi AR, Akhlaghi M, Sadeghi Abdollahi B, Ziaie N, Akbarian M, Gharibdoost F. Management of ocular manifestations of Behcet's Disease: outcome with cytotoxic drugs. APLAR Journal of Rheumatology 2005; 8: 119-123</citation>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>November 19, 2010</last_update_submitted>
  <last_update_submitted_qc>November 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fereydoun Davatchi, Head Rheumatology Research Center</name_title>
    <organization>Rheumatology Research Center, Tehran University for Medical Sciences</organization>
  </responsible_party>
  <keyword>Etanercept</keyword>
  <keyword>Behcet's syndrome</keyword>
  <keyword>Behcet's Disease</keyword>
  <keyword>Ocular Lesions</keyword>
  <keyword>Uveitis</keyword>
  <keyword>Retinal Vasculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Uveal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

